Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.54 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737413 | 0.91 | PFKFB3 (0.56) | POLBCA2AKR1C3AKR1C2PFKFB3 | |
| SCHEMBL5432947 | 0.86 | ALDH1A1 (0.67) | POLBCA2ALDH1A1MEN1KMT2A | |
| SCHEMBL4599829 | 0.84 | ALDH1A1 (0.58) | POLBPFKFB3ALDH1A1MEN1KMT2A | |
| SCHEMBL691076 | 0.83 | GAA (0.60) | POLBCA2ALDH1A1MEN1KMT2A | |
| SCHEMBL11853651 | 0.83 | CA2 (0.52) | POLBCA2PFKFB3ALDH1A1CA1 | |
| SCHEMBL13719772 | 0.83 | CA2 (0.52) | POLBCA2ALDH1A1LMNACA1 | |
| SCHEMBL14038512 | 0.82 | CA2 (0.51) | POLBCA2ALDH1A1CA1MAPK1 | |
| SCHEMBL16536451 | 0.82 | CA2 (0.51) | POLBCA2ALDH1A1CA1MAPK1 | |
| SCHEMBL27621213 | 0.82 | CA2 (0.51) | POLBCA2PFKFB3ALDH1A1LMNA | |
| SCHEMBL3792523 | 0.82 | CA2 (0.48) | POLBCA2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7312360-B2 | Substituted hydroxyethylamines | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312360-B2 | Substituted hydroxyethylamines | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| CN-1744899-A | Piperidine derivatives as CCR5 antagonists | SMITHKLINE BEECHAM CORP (US) | 2006-03-08 | — | — | CN | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096942-A1 | Substituted Hydroxyethylamines | BACE1, BACE2, MME | POLB 621/4885CA2 3235/4885AKR1C3 1615/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | POLB 1541/4885CA2 4267/4885AKR1C3 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.